Lung Cancer Screening Market size was valued at USD 1,768.1 million in 2021, growing at a significant CAGR of 6.5% over 2022-2028. A type of disease that occurs in the lungs is known as lung cancer. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the 2 main types of lung cancer and are treated differently. The non-small cell lung cancer segment anticipated to grow at significant CAGR over the forecast years owing to non-small cell lung cancer are the most common type of cancer accounted for approximate 85% of all lung cancers. However, non-Small cell Lung cancer metastasizes to other organ slower in compression to SCLC, and microscopically , SCLC is composed of much smaller cells. if untreated, SCLC can be fatal in few weeks, in contrast to most cases of NSCLC. Moreover, as per the research Non–small cell lung cancer accounts for 85% of all lung cancer cases in the United States after the initial diagnosis. The prevalence of lung cancer cases worldwide, greater emphasis on technological developments in the production of medical devices, and rising spending on the expansion of healthcare infrastructure, particularly in developing economies, are the main drivers of the lung cancer screening market.